Quantcast

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Research paper by Harold L Atkins, Marjorie Bowman, David Allan, Grizel Anstee, Douglas L Arnold, Amit Bar-Or, Isabelle Bence-Bruckler, Paul Birch, Christopher Bredeson, Jacqueline Chen, Dean Fergusson, Mike Halpenny, Linda Hamelin, Lothar Huebsch, Brian Hutton, et al.

Indexed on: 08 Oct '16Published on: 09 Jun '16Published in: The Lancet



Abstract

Strong immunosuppression, including chemotherapy and immune-depleting antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been used to treat patients with multiple sclerosis, improving control of relapsing disease. We addressed whether near-complete immunoablation followed by immune cell depleted aHSCT would result in long-term control of multiple sclerosis.

Figure 10.1016/S0140-6736(16)30169-6.0.gif
Figure 10.1016/S0140-6736(16)30169-6.1.jpg
Figure 10.1016/S0140-6736(16)30169-6.2.jpg
Figure 10.1016/S0140-6736(16)30169-6.3.jpg
Figure 10.1016/S0140-6736(16)30169-6.4.jpg

More like this: